DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium
2017
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
3
Citations
NaN
KQI